The informational and digital era of Big Data presents a non-trivial and unprecedented way in history for data and information management in organizations. Thus, to manage, protect, and ensure the validation of this data, it is imperative to develop new technologies for project management and their respective implementation in organizations. This chapter shows a case study in a pharmaceutical industry with the proposition of a methodology for validation of emerging technologies in the computerized systems. Data validation and security for project management in the organization is increasingly in demand. So, this implies that time and human resources in organizations are not infinite. It is necessary to prioritize the activities and resources dedicated to maintaining the validated state of the system. Authors propose a risk analysis to help companies with validation. They also present a proposed methodology for risk analysis from the point of view of the validation of computerized systems in a Warehouse Management module in a validated SAP ERP.
1 August 2026 in Research, Society and Development
O presente trabalho tem como objetivo utilizar informações técnicas extraídas de documentos de patente para identificar Atributos Críticos de Qualidade (CQAs), Atributos Críticos de Materiais (CMAs) e Parâmetros Críticos de Processo (CPPs) em formulações de suspensões de ibuprofeno. A metodologia adotada consistiu na realização de buscas estruturadas na base Espacenet, com o uso de classificações internacionais de patentes e palavras-chave específicas, seguidas por uma análise técnica das informações extraídas. Posteriormente, foi aplicada uma análise de risco por meio da ferramenta FMEA (Failure Mode and Effects Analysis) para identificação dos CPPs. Os resultados evidenciaram que os documentos de patente fornecem dados sobre composição, processos de fabricação e controles aplicáveis, destacando fatores qualitativos como o tamanho de partícula do insumo ativo, a ordem de adição dos componentes, a hidratação de agentes suspensores, a formação da rede tixotrópica e a deaeração a vácuo. A aplicação dos conceitos de Quality by Design (QbD), associada à análise de risco, permitiu estruturar o conhecimento técnico do processo e identificar pontos críticos, oferecendo suporte à otimização de processos e à condução de transferências tecnológicas robustas em produtos legados.
21 June 2024 in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
Introduction: Providing quality, safe, and effective medicine is the purpose of the production and supply chain; however, errors happen. This work addresses action against defects observed in medicines’ primary and secondary packaging from the perspective of health and consumer administrative legislation and their practical consequences in the consumer relationship. Objective: To demonstrate the contribution of health and consumer administrative legislation, with emphasis on Good Manufacturing Practices (GMP) for medicines and the Consumer Protection Code, ensuring adequate and safe information to patients and how suppliers and consumers can influence the control of defects and safe administration of medicines, before, during, and after sale. Method: Adoption of descriptive and explanatory research, a documental nature bibliographical using checklist for direct observation register, about a qualitative and quantitative approach. Results: It was identified that current resolution about GMP applied at medicines have 34 control mechanisms that contribute to avoiding defects in packaging operations, an advance for patient safety. In addition, in all legislative frameworks analyzed, there was a protection of consumerist principles of transparency in information, objective good faith and security. However, there were gaps in the use and knowledge of information and safety devices in packaging materials. Highlighting the practice of changing medications without regulatory provisions as a problem for communicating product defects to the manufacturer and increasing health risk. Conclusions: Despite legislative evolution to combat defects, consumers and pharmacies need more knowledge, awareness, and adequate use of complaint channels. The return/exchange of medicines is a potential sanitary risk that needs to be confronted and perhaps better regulated.